论文部分内容阅读
目的:探讨孟鲁司特钠辅助治疗支气管哮喘的临床疗效。方法:选取在我院接诊的60例支气管哮喘患者作为主要研究对象,并将其随机性分为两组,即观察组和对照组,每组30例患者,其中对照组患者接受布地奈德治疗,观察组患者接受孟鲁司特钠辅助治疗,对两组患者的临床效果进行观察,比较和分析两组患者的临床疗效。结果:两组患者通过治疗,观察组患者的总有效率为96.7%,对照组患者的总有效率为80.0%,观察组的总有效率较高,与对照组比较,差异具有统计学意义(P<0.05,X2=4.0431)。结论:在支气管哮喘的临床治疗过程中,孟鲁司特钠具有较好的临床效果,促进患者肺功能的恢复,值得临床推广和使用。
Objective: To investigate the clinical efficacy of montelukast sodium adjuvant therapy for bronchial asthma. Methods: Sixty patients with bronchial asthma admitted to our hospital were selected as the main study subjects. The randomized patients were divided into two groups: the observation group and the control group, with 30 patients in each group. The patients in the control group received budesonide The patients in the treatment group and the observation group received adjuvant montelukast adjuvant therapy. The clinical effects of the two groups were observed, and the clinical efficacy of the two groups was compared and analyzed. Results: The total effective rate was 96.7% in observation group and 80.0% in observation group. The total effective rate in observation group was higher than that in control group, the difference was statistically significant ( P <0.05, X2 = 4.0431). Conclusion: In the course of clinical treatment of bronchial asthma, montelukast sodium has good clinical effect, promote the recovery of lung function in patients, worthy of clinical promotion and use.